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ABSTRACT
Objective Clinical trials and studies in intensive care 
units (ICUs) have complex consent processes and often 
encounter problems in recruiting patients. By interviewing 
research team members about the challenges in critical 
care research, we aimed to identify strategies to enhance 
recruitment and consent to ICU studies.
Methods Semistructured interviews with UK- based 
researchers (N=17) and patient–public involvement (PPI) 
contributors (N=8) with experience of ICU studies. Analysis 
of transcripts of audio- recorded interviews drew on 
thematic approaches.
Results Seven themes were identified. Participants 
emphasised the need for substitute decision- making 
processes in critical care studies, yet some researchers 
reported that research ethics committees (RECs) were 
reluctant to approve such processes. Researchers spoke 
about the potential benefits of research without prior 
consent (RWPC) for studies with narrow recruitment 
windows but believed RECs would not approve them. 
Participants indicated that the activity of PPI contributors 
was limited in critical care studies, though researchers 
who had involved PPI contributors more extensively were 
clear that their input when designing consent processes 
was important. Researchers and PPI contributors pointed 
to resource and staffing limitations as barriers to patient 
recruitment. Researchers varied in whether and how 
they used professional consultees as substitute decision- 
makers, in whether they approached families by telephone 
to discuss research and in whether they disclosed details 
of research participation to bereaved relatives.
Conclusion Critical care research could benefit from 
RECs having expertise in consent processes that are 
suited to this setting, better staffing at research sites, 
more extensive PPI and an evidence base on stakeholder 
perspectives on critical care research processes. Guidance 
on professional consultee processes, telephoning relatives 
to discuss research, RWPC and disclosure of research 
participation to bereaved relatives could help to harmonise 
practice in these areas and enhance recruitment and 
consent to critical care studies.
INTRODUCTION
Clinical research in intensive care units 
(ICUs) is essential for improving care and 
treatments for critically ill patients. However, 
patients often lack decisional capacity at 
the point when they are recruited to critical 
care studies and the ‘gold standard model’ 
of consent, where an autonomous patient 
makes an informed decision about whether 
to take part in research, is not applicable.1 2 
To make sure patients can benefit from the 
improvements to care that research brings, 
regulations have been developed in many 
countries to permit enrolment of incapaci-
tated patients.3–5 These aim to balance the 
rights of these patients with the need for 
research in ICUs and other settings where 
patients do not have capacity.6 Box 1 below 
summarises the regulations governing recruit-
ment and consent of incapacitated patients to 
research in England and Wales, as outlined by 
the Health Research Authority (HRA), while 
variants of these requirements apply in Scot-
land and Northern Ireland.
Despite regulations permitting recruitment 
of incapacitated patients to studies, success-
fully implementing research and recruiting 
Strengths and limitations of this study
 ► The study includes the views of UK- based research-
ers and patient–public involvement (PPI) contribu-
tors to explore the problems that research teams 
encounter in recruiting and consenting to intensive 
care unit (ICU) studies.
 ► A sample of just eight PPI contributors limits the 
scope of perspectives included in this study, though 
does reflects researchers’ reliance on a small pool of 
PPI contributors for their studies.
 ► Most of the studies discussed at interview were in-
terventional and there may be distinct issues in re-
cruiting and consenting to observational ICU studies 
that our findings do not cover.
 ► We focused on UK- based participants, so transfer-
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patients in critical care settings can be challenging. A 
review by Schandelmaier et al7 found that trials in emer-
gency care and ICUs are four times more likely to be 
prematurely discontinued due to slow patient recruit-
ment compared with trials outside these settings. Approx-
imately 44% of randomised control trials do not meet 
their recruitment targets.8 In addition to the recruitment 
barriers that are widely reported in many specialties,9–13 
critical care trials face numerous specific challenges.7 14 
Several of these challenges arise from the time- sensitive 
nature of treatments in this setting, with necessarily 
short time windows for recruitment of patients for many 
studies. Recruitment often takes place out of hours, when 
staffing and other resourcing may not be adequate to 
support research demands and family members are often 
not available or able to act as substitute decision- makers. 
However, Schandelmaier et al7 noted that studies in their 
review rarely reported detailed reasons for recruitment 
problems.
To better understand the challenges in recruiting 
and consenting incapacitated patients to research in 
critical care settings, we conducted in- depth qualitative 
interviews with critical care research staff in the UK. As 
we were particularly interested in understanding the 
interface between the legal frameworks around consent 
processes and the practicalities of implementing recruit-
ment to ICU studies, interviews explored what influenced 
researchers when designing recruitment and consent 
processes, as well as their experience of recruiting to 
studies. Our overall goal was to identify ways that recruit-
ment and consent could be enhanced in ICU studies. 
To ensure studies are designed and implemented in 
ways that are patient centred, researchers in a growing 
number of countries are now expected to involve patients 
and the public when designing and implementing 
studies.15–21 Therefore, we also interviewed people who 
had been patient–public involvement (PPI) contributors 




Interviews were conducted between late 2016 and mid 
2017 as one workstream within the wider mixed methods 
perspectives study. The perspectives study sought to 
develop good practice guidance on recruitment and 
consent processes for ICU studies. Given these pragmatic 
aims, the study was broadly critical realist in approach.
Patient and public involvement
This study included two PPI contributors, who were not 
specifically involved in this workstream.
Sampling and recruitment
We sampled UK researchers who had experience of 
designing or conducting ICU studies by searching the 
National Institute for Health Research research portfolio, 
Box 1 Overview of approaches to recruitment and 
consent seeking with incapacitated patients in England 
and Wales* by study type
(1) Clinical trials of investigational medicinal products 
(CTIMPs)
CTIMPs in non- emergency situations
Investigators can seek prospective consent from an incapacitated pa-
tient’s legally designated personal representatives. Personal represen-
tatives are personally known to the patient, such as a family member 
or a close friend. However, if there is no representative, they are not 
available or they are unwilling to act (ie, you can not contact them or 
they do not want to make that decision), a doctor who is independent 
of the study can act as a legally designated professional representative 
and approve a patient’s recruitment to a trial in certain circumstances. 
Researchers will usually seek consent (eg, for continued participation 
and further disclosure of confidential information) from the patient, if 
and when they regain capacity.
CTIMPs in emergency situations
When investigating treatments that must be administered urgently 
and it is not reasonably practicable to obtain consent from a legally 
designated representative, patients can be recruited into a trial with-
out prior consent. This is known as research without prior consent. As 
patients recruited under this process may regain capacity to give con-
sent, researchers are required to plan how they will involve patients 
in the on- going consent process. Trial participation and any relevant 
consent required (eg, consent for continued participation and disclosure 
of confidential information) should be discussed with legally designated 
representative, or patient if they regain capacity, as soon as possible 
after the patient’s recruitment to the trial.
(2) Other study types (non- CTIMPs)
Other study types are those that involve the processing of personal data, 
administration of interviews or observations and clinical trials that are 
not CTIMPs.
Other types of study in non- emergency situations
Before a patient is recruited to such a study, investigators are required 
to seek advice from the patient’s personal consultee, usually a family 
member, about the patient’s likely wishes. If investigators are unable to 
identify a personal consultee, they can consult with a nominated con-
sultee, which is usually a doctor responsible for the patient’s care who 
has no connection to the research. When a patient recruited under a 
consultee process subsequently regains capacity, study participation 
should be discussed.
Other types of study in emergency situations
Patients can be recruited without prior advice from a consultee, 
provided it is not reasonably practicable to seek such advice in ad-
vance. Investigators need to seek agreement of a registered medical 
practitioner who is not involved in the organisation or conduct of the 
study—unless there is insufficient time to obtain that agreement. The 
consultee’s advice should be sought on the participant’s likely views 
and feelings about the study as soon as possible after recruitment. If 
objections are raised, the patient must be withdrawn unless doing so 
would pose a risk to the participant’s health. When a patient recruited 
under a consultee process subsequently regains capacity, study partic-
ipation should be discussed.

















pen: first published as 10.1136/bm






3Paddock K, et al. BMJ Open 2021;11:e048193. doi:10.1136/bmjopen-2020-048193
Open access
trial registries and snowball sampling via critical care 
researchers and networks. Researchers were eligible 
if they had been involved in critical care studies which 
had included at least one UK centre and was in set up, 
ongoing or had been published within the previous 2 
years. We sent researchers an invitation email outlining 
the perspectives study and attached a participant infor-
mation sheet with further details.
PPI contributors were eligible if they had been research 
partners, steering group members or advisors on ICU 
studies. We initially identified them by asking interviewed 
researchers to email PPI contributors who they had 
recently worked with. Researchers sent PPI contributors 
an invitation email and a participant information sheet. 
We identified relatively few PPI contributors via this route, 
at least in part because research teams often seemed 
to rely on the same few PPI contributors for multiple 
studies. Therefore, we also placed an advertisement for 
potential PPI participants in a newsletter that ICUsteps, a 
UK charity for ICU patients and families,22 circulated to 
their members. A total of 15 PPI contributors responded 
to our requests for participants and 8 were interviewed. 
Five did not respond to arrange an interview date and two 
declined over concerns they might breach the confidenti-
ality of the study they were involved in.
KP contacted researchers and PPI contributors who 
replied to the invitation, further explaining the study and 
arranging the interviews. Sampling of participants aimed 
for data saturation, the point at which further interviews 
no longer add to the analysis.23
Interviews
The interviews were conducted by KP, a postdoctoral 
research psychologist with experience in qualitative 
methods. Interviews were semistructured to ensure key 
topics were explored, while also conversational to enable 
participants to raise previously unanticipated issues. To 
avoid idealised responses, interviews focused on specific 
studies that participants had been involved with. The 
interview topic guide (box 2) was initially informed by the 
published literature and the research team’s experience 
in this area and then developed iteratively over the course 
of interviewing. As participants were located throughout 
the UK, interviews were conducted via telephone. Partic-
ipants gave informed consent before being interviewed 
and PPI contributors were offered a £25 shopping 
voucher to acknowledge their contribution to the study.
Analysis
Transcripts of audio- recorded interviews were checked 
for accuracy and pseudoanonymised prior to analysis. KP 
led the analysis in close consultation with BY (a psychol-
ogist and qualitative methodologist); both read all tran-
scripts multiple times. Analysis was broadly interpretive 
and informed by the literature on quality and rigour in 
qualitative research.24 We drew on thematic approaches25 
but conducted the analysis at multiple levels, from line by 
line coding, to consideration of participants’ narratives at 
a holistic level in order to ensure coherence and contex-
tualisation. The developing analysis was discussed with 
wider members of the study team, which included indi-
viduals with expertise in qualitative methods, bioethics, 
critical care, and clinical trials. We used NVivo software to 
assist with indexing and coding the data.
To evidence our interpretations we present data 
excerpts, denoting researchers with an R before their 
identification code and PPI contributors with P.
RESULTS
Participant and interview characteristics
We invited 26 researchers and interviewed 17 (65%); the 
remaining nine researchers did not respond to invita-
tion emails. Of the 17 interviewed researchers (10 male, 
7 female), 10 were consultants and one was a specialist 
registrar in intensive care medicine. The remaining six 
had backgrounds in academic research, clinical trial 
management or nursing in intensive care settings. Eight 
had 15 or more years’ experience in critical care research, 
seven had between 5 and 14 years and two had less than 
4 years critical care research experience. A total of 15 PPI 
contributors responded to the study team to express an 
interest in participating and we interviewed eight. As we 
recruited PPI contributors via participating researchers 
and an advertisement, we are unable to report how many 
received invitations but did not respond. Of the eight 
PPI contributors (six male, two female), all except two 
reported that they had lived experience of ICU care as a 
patient, relative or both.
Interviews usually lasted between 45 min and 60 min. 
A total of 33 ICU studies were discussed (4 observational, 
Box 2 Summary of topic guides for researchers and 
patient–public involvement (PPI) contributors
Interviews with researchers explored their accounts of:
 ► Ethical, regulatory, scientific and pragmatic considerations that 
guided decision- making about the design of recruitment and con-
sent methods in their studies.
 ► Experiences of seeking ethical approval and feedback from research 
ethics committees.
 ► Experiences of implementing different recruitment and consent 
processes, including the timing of recruitment, consultation and 
consent seeking and involvement of different staff in this process.
 ► Perceived barriers to implementing recruitment and consent as 
planned.
 ► Suggestions for improving recruitment and consent processes.
Interviews with PPI contributors explored their accounts 
of:
 ► Recruitment and consent processes in intensive care unit studies 
they had been involved with.
 ► Awareness of considerations that had informed recruitment and 
consent processes.
 ► Opinions of these recruitment and consent processes.
 ► Awareness of any problems that arose during the studies.
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29 interventional), although some PPI contributors had 
difficulty remembering details of the studies they were 
involved in.
Qualitative findings
The present findings are organised in seven themes. We 
turn first to participants’ accounts of the design of recruit-
ment and consent processes, before presenting their 
perspectives on the practical implementation of these 
processes in studies. We note that the terminology used by 
participants often differed to that used in guidance and 
regulations. For brevity and reflecting the terminology of 
participants, we use the term consultee to refer to substi-
tute decision- makers in both clinical trials of investiga-
tional medicinal products (CTIMPs) and non- CTIMPs.
Designing recruitment and consent processes
Designing consent processes was felt to be straightforward but 
often lacked PPI
Unsurprisingly, researchers spoke of regulatory require-
ments as an important influence on the design of their 
studies. Some specifically mentioned following a three 
tier consent ‘hierarchy’ (R20) in which informed consent 
from patients was regarded as the most acceptable 
process, with consultation with a personal consultee as 
intermediate and use of professional consultees reserved 
for instances when patient informed consent and a 
personal consultee process was not possible.
The hierarchy is, er, patient consent, if patient con-
sent is not possible then declaration by a person-
al consultee. If the personal consultee is either not 
available or it’s not appropriate to consult them, it’s 
a declaration by a nominated [professional] consult-
ee… a critical care consultant who is not immediately, 
who is not involved in the research study and is not 
immediately involved in the care of the patient. (R20)
Beyond this hierarchy, researchers commented that 
the design of the recruitment and consent processes 
was relatively straightforward and largely determined by 
study type and the overall research aims, ‘it’s dictated by 
what the study is and what you’re err trying to demon-
strate’ (R11). They carried forward processes that they 
had used in previous studies ‘we just really used the same 
process for the second study, it was, you know, pretty 
much accepted’ (R15) and emphasised the many years of 
ICU clinical and research experience that they and their 
teams had to draw on when designing recruitment and 
consent processes.
Several researchers described having consulted with 
PPI contributors about their studies. A few believed that 
PPI contributors had an important role in informing 
consent processes. For example, R19 commented that PPI 
contributors had influenced their research team’s deci-
sion to take a ‘proportionate’ approach to the consent 
process in their study of using a professional consultee 
process when relatives were unavailable or speaking with 
them would pose an ‘unnecessary or excessive burden on 
relatives at a difficult time’. However, most researchers 
indicated that consultation with PPI contributors had 
largely involved them commenting on study patient 
information materials rather than directly informing the 
design of recruitment and consent processes. While one 
researcher said that PPI input ‘wasn’t necessary’ (R11), 
more commonly researchers believed PPI input to the 
design of recruitment and consent processes was limited 
because ‘you needed to be a clinician to understand the 
parameters’ (R13).
Echoing the accounts of researchers, PPI contribu-
tors mostly described having limited input to the design 
of recruitment and consent processes with their roles 
largely being to comment on patient and family informa-
tion materials and attend study steering group meetings. 
Also echoing the accounts of some researchers, several 
PPI contributors commented that their input was limited 
by their lack of clinical knowledge. However, some also 
linked their limited input to how research teams imple-
mented PPI. For example, PPI being sought after the 
design of studies was largely settled, studies only having 
one PPI member and a lack of support and training for 
PPI contributors, ‘there’s no training for PPI… it can be 
a very daunting environment for someone who is perhaps 
retired and has come from a relatively ‘normal’ back-
ground’ (P25). One PPI contributor also commented 
that some critical care researchers were ‘half- hearted’ 
(P6) about PPI and did not use it to its full potential.
Anticipated challenges of gaining ethics approval influenced the 
design of some studies
Researchers’ experiences of preparing for and gaining 
research ethics committee (REC) approval for their 
studies were mixed. Some indicated that gaining REC 
approval was ‘very straightforward’ (R11). This included 
several researchers who had obtained approval to use 
substitute decision- makers in their studies. Outlining the 
REC’s rationale for approving enrolment to their study 
via a ‘declaration by a nominated consultee’ where neces-
sary, R20 explained:
The reason the ethics committee agreed… we were 
keen to have a blood test on the day of severe acute 
[name of condition] and… they also accepted that 
the relatives are not always available and even if they 
are available, they may be too distressed.
Some researchers commented that they and their study 
teams had become adept in understanding what ethics 
committees would or would not approve. One described 
having ‘built up a relationship’ (R7) with an REC and 
working in a mutual learning cycle, whereby the REC 
gained experience in reviewing studies involving inca-
pacitated patients, while their research team used the 
REC’s feedback over numerous previous studies to cumu-
latively fine tune their processes and patient materials for 
new applications. Similarly, another researcher spoke of 
selecting RECs who were experienced in dealing with ICU 
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you have a difficulty it’s because you’ve gone to the wrong 
REC’ (R18). The feedback such researchers received 
from RECs on their applications largely amounted to 
minor revisions to patient information materials.
Others described the challenges they had encountered 
in gaining approval for their studies. These researchers 
felt RECs were ‘negative’ (R11) and described instances 
of RECs refusing to approve consent processes that were 
commonplace in ICU studies.
Making you justify, endlessly, why, in an incapacitated 
patient, you can't take a form of consent. It’s like an 
uphill battle… Despite going and justifying the ra-
tionale, they tend to just come back and say ‘no, we 
don't want you to do that, we want you to take writ-
ten consent or we want you to try without telephone 
consent and if you're struggling to recruit, come back 
to us and then we'll give you, then we might give you 
telephone consent. (R4)
Commenting on the narrow time windows of many ICU 
studies, several researchers were interested in whether 
research without prior consent (RWPC) would help 
to address such challenges. However, one researcher 
described having been denied REC permission for RWPC 
in their study, while others commented that they had 
anticipated problems in ethical gaining approval for 
RWPCi and so had a priori ruled out RWPC when devel-
oping their funding and ethics applications. R8 explained 
the potential implications for investigating the efficacy of 
the time- sensitive study intervention in their study.
If therapies aren't started within a specific, um, time 
window… their potential, um, efficacy might be 
lost… we're currently trying to get a sedation study 
funded and we think that using it very early is likely to 
be beneficial but we're probably going to, um, com-
promise that because we know we won't be able to get 
consent quickly enough if we don't get, um, deferred 
consent. (R8)
Similarly, R1 attributed their team’s previous decision 
not to seek REC approval for RWPC in a study to the diffi-
culty of justifying the use of RWPC. R1 linked this diffi-
culty to a lack of evidence on stakeholder perspectives 
on RWPC at the time the team were designing the study 
and noted that evidence of stakeholders’ perspectives on 
RWPC had since been published in the context of paedi-
atric emergency and critical care studies.
We just couldn’t see how we could quite justify it 
[RWPC], but I think we might have had a go at justi-
fying it by using a lot of the other work that’s going on 
at the moment, especially through some of [name of 
researcher]’s stuff… I would have been a bit braver. 
(R1)
i Several interviewees used terms such as ‘deferred consent’ or 
‘emergency provision’ to refer to RWPC.
Without recourse to RWPC, R1 suggested that their 
study was ‘delaying treatment essentially’ and elaborated 
on the concerns this raised: ‘my main worry…. in the real 
world you would be starting that protocol at the point 
of when they’ve met the eligibility criteria… rather than 
an hour and a half later’ (R1). Speaking of the ‘lack of 
clarity’ regarding RWPC as a ‘major, major challenge 
for critical care research’, R4 pointed to differences in 
attitudes towards RWPC between the HRA (the national 
authority in the UK that oversees governance in health-
care research) and individual ethics committees.
The people at the top were very clearly saying if the 
[consent] process is delaying when you feel this bio-
logical plausibility of the intervention should occur, 
you should be going to the ethics committee and say-
ing, I need to have emergency provision because of 
that, whereas my experience is when you go to indi-
vidual ethics committees, that that’s not the view a lot 
of them take. (R4)
Despite these and other challenges, few researchers 
commented on input from PPI contributors as being rele-
vant on such issues when seeking REC approval, although 
some did comment in more general terms about PPI 
input being helpful in discussions with ethics committees.
Make sure that there are some PPIs to feed into… 
that also creates very sort of strong basis for discus-
sions with the ethics committee… otherwise you go 
into these things without sort of a leg to stand on if 
they don’t feel it’s the right, but if you’ve been able 
to discuss it with the ethics committee based on feed-
back from patients… it makes it a lot stronger. (R1)
Again, concurring with the accounts of most researchers, 
the PPI contributors we interviewed commented that they 
had provided little or no input to the REC applications 
for the ICU studies that they were involved with.
Implementing recruitment and consent processes
Need for alternatives to prospective informed consent from 
patients
In their accounts of implementing research, almost all 
researchers and several PPI contributors emphasised the 
difficulty of obtaining prospective informed consent from 
patients in the ICU and the need for substitute decision- 
makers. Recruiting patients was often a ‘24/7’ (R4) activity 
and patient eligibility for a study could change rapidly, yet 
staff support for research was costly and usually only avail-
able during office hours. Moreover, as both PPI contrib-
utors and researchers commented, much critical care 
research was time critical and study recruitment windows 
often did not coincide with relatives being present to act 
as personal consultees.
Things can happen so fast and… well if the relative’s 
gone home and suddenly there’s been a deteriora-
tion or there’s, you know, where they think hang on 
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Well you could be waiting six hours for the relative to 
come back in. (P21)
You're having to do this time sensitive, face to face 
with the relative at an appropriate time… then 24/7 
recruitment is really challenging because it’s very dif-
ficult to staff your ICU seven days a week… into the 
evenings… the cost of staffing you're doing is very 
high. (R4)
While emphasising the need for substitute decision- 
makers, some researchers worried that regulation 
permitting such consent was precarious and spoke of 
the potential for future changes that could, for example, 
restrict the use of substitute decision- makers and make 
ICU research ‘even more difficult to undertake’ (R13) 
and be ‘disastrous for critical care, um, because it just, it 
would, it would preclude research really’ (R12).
Challenges of using personal consultees
Both researchers and PPI contributors described the 
complexities of approaching family members to act as 
personal consultees when patients were incapacitated. 
They emphasised that family members are in a ‘frantic 
state’ (R2) when patients are critically ill with feeling of 
anxiety going ‘through the roof’ (P21) and the difficulties 
families would have in taking in information and making 
a decision about a study. In this context, PPI contribu-
tors spoke of the need for researchers to be ‘very gentle’ 
(P9) when approaching families, while researchers spoke 
of their strong urge not to add to the families’ distress 
and of the tensions appropriately timing the approach 
to families when studies often required consultation with 
family members very soon after a patient’s admission to 
ICU and ‘there’s a lot of anxiety from the relatives’ (R11). 
They also described family members as sometimes being 
reluctant to make decisions about research on behalf of 
the patient and as ‘much more risk averse…than they 
[patients] would’ve been for themselves’ (R15). When a 
patient had multiple family members, difficulties could 
also arise in establishing who should act as a patient’s 
personal consultee and sometimes family members could 
not agree about whether a patient should be recruited. 
Several researchers also spoke of the complexities of 
contacting families by telephone to discuss research. A 
few were reluctant to do so and one researcher indicated 
that their REC was reluctant to permit families being 
approached about research over the telephone. Such 
complexities led some researchers to question whether 
involving family members in decisions about research, in 
the hours after a patient’s admission, was necessarily supe-
rior to the use of professional consultees or RWPC.
Are we kidding ourselves that we’re doing some truly 
ethical process where actually, would it be best to just 
use [RWPC] and say you know, this has been through 
a whole load of checks and balances? (R2)
I feel that it’s more ethic, it’s more ethical to use 
the professional consent and to gain consent from 
relatives when they are in the, you know, when they 
are kind of feeling more comfortable and less panicky 
about what’s happened to their relatives. (R13)
Challenges of using professional consultees
In contrast, a few researchers were uneasy about the use 
of professional consultees for other reasons. Indeed, one 
spoke of making strenuous efforts to ‘avoid’ this process, 
noting concerns about how it might be perceived ‘exter-
nally’. (R3)
You can see how it could be externally perceived that 
the consultant who signs as the professional consultee 
could seem to have a conflict of interest with regards 
to not upsetting his colleague who is the investiga-
tor… We've always usually, by hook or by crook, been 
able to identify a personal consultee. (R3)
Other researchers spoke about whether to ‘go to a 
professional legal representative vs wait for the relatives’ 
as ‘a grey area’ (R4). They varied in how they managed 
this, with some tending to reserve professional consultees 
for situations where family members could not be traced 
within a given period.
Where we know there’s a next of kin but they can't 
come up face to face. And in that setting we would 
lose the patient 'cause we generally only use a profes-
sional where there are, is no next of kin at all or we're 
not aware of any next of kin following a, um, detailed 
search. (R8)
A few researchers described more flexible processes 
in which they extended use of professional consultees to 
situations where it was considered burdensome or unfea-
sible to ask families to make a decision.
If it looks like the family are going to come in then 
we’ll wait for them and talk to them. But if it’s go-
ing to be not feasible, or there is some reason why it 
would be very last minute to talk to them, and, you 
know, disproportionate or unfair on them, then we 
have an ability to take the professional advice. (R19)
R19 added that they reserved the use of professional 
consultees only for studies that involved treatments 
already in widespread clinical use, whereas for studies 
involving more novel treatments the patient would not 
be recruited without first speaking to the family. A variant 
on the above process involved researchers contacting the 
family members in advance of a patient’s recruitment to 
inform them of a plan to recruit the patient to a study 
under a professional consultee process. R19 and R15 
referred to using this process, although with some unease 
on R15’s part.
If the relative was in Australia for instance we would 
tell them about the trial, see if they had any objec-
tions, and then we would get professional consent…
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Regardless of the different perspectives and arrange-
ments surrounding the use of professional consultees, 
some researchers commented that family members were 
generally accepting of this process when told about it 
‘after the event’, often readily endorsing the patient’s 
continued participation in a study. ‘If you’d obtained a 
physician consent… then people are often very happy 
to say that’s great, I don’t have any objections to you 
carrying on. But if you ask them to give the consent then 
they would be reluctant to make a decision’. (R18)
Those PPI contributors who spoke about professional 
consultee processes felt that it was acceptable ‘if the 
safeguards are all in place… I’m quite comfortable with 
that’ (P17), although several expressed some reluctance 
or attached caveats to their support. ‘I’m just a little bit 
wary… you just need a couple of caveats of, in there about 
who it is doing it, and that they’re sufficiently indepen-
dent to actually take in the patient’s best interests’ (P6).
Challenges of seeking consent from patients after they regain 
capacity
For patients who regain capacity after being recruited 
to studies under a personal or professional consultee 
process, it is a requirement for researchers to seek the 
patient’s consent. However, as researchers remarked, 
patients ‘may appear to have capacity’ (R4) but this could 
fluctuate rapidly and they could have an array of some-
times subtle physical, cognitive and emotional difficulties 
influencing their capacity. As R13 noted: ‘they're not criti-
cally ill but… they're still nowhere near 100% and I'm not 
sure they've got real energy to think about [research]’. 
PPI contributors echoed these comments:
If I’ve just been woken up from a ventilator or seda-
tion or I’m going into high dependency from ICU 
do I really want papers, documents, people coming 
to me and talking about the study and wanting my 
signature. (P24)
Therefore, judging when a patient could be approached 
about a study was challenging: ‘the ability of the research 
staff, even if they're very experienced, to assess that is also 
very, very difficult’ (R4) and often involved researchers 
returning to assess a patient several times.
Consenting I would say is one of the most time- 
consuming things that the research nurses do. So 
they’ll often have to go back and see people, either 
on the ICU or in the ward, three, four, maybe five 
times before people actually regain capacity and they 
can actually consent them. (R11)
Complexities could also arise if samples or other study 
procedures were required soon after a patient had started 
to regain consciousness: ‘once a patient is awake and kind 
of aware then you can’t really approach them for a study 
procedure without telling them about the study… they’re 
just realising how sick they were… it’s just all too much’. 
(R18)
Challenges when a patient dies
With mortality rates in ICUs of around 25%, some 
patients recruited to studies will not survive their illness. 
Where patients recruited to studies under a professional 
consultee process subsequently die, bereaved family 
members may be unaware that their deceased relative 
participated in a study.11 Researchers who had encoun-
tered this issue varied in their accounts of how they 
managed it. One indicated that their practice was to 
inform bereaved relatives about the patient’s participa-
tion and ask them whether they wished the patient’s data 
to be retained in the study.
By the time you’ve got to the relatives the patient has 
already died, then you would…. tell them that before 
[the patient] died they were put in a study, and, er, 
that [the family members] just need to be aware of 
that… you’ve obtained professional consent then you 
would give the relatives the option to say ‘do you wish 
the data to be used or not used? (R18)
In contrast, R4 did not discuss the research with 
bereaved relatives and referred to published guidance to 
support their team’s practice.
In England, under the professional legal representa-
tive… our understanding from the guidance we had 
was if the patient died and we didn't have any oth-
er form of consent or non- objection we could retain 
the patient in the study, because under the Mental 
Capacity Act, the professional legal representative 
was a valid form of documentation to include some-
one in a study. (R4)
In line with the advice from their PPI group, R19 simi-
larly described their usual practice was not to inform 
bereaved relatives that the patient had taken part in a 
study, unless there were exceptional circumstances.
Our patient and public groups think that on the 
whole unless there’s a particular reason why you need 
to tell the relatives, er, why something happened, they 
don’t really want us approaching relatives of patients 
who’ve died… We do sometimes, but on average no, 
it’s very study specific. If […] a serious adverse event 
has occurred then we would, because we’ve got a duty 
to disclose. (R19)
While perspectives on this issue varied, researchers 
agreed that further guidance was needed on whether and 
how to disclose study enrolment and retention of data to 
families, when a patient recruited under a professional 
consultee process subsequently dies.
PPI contributors who spoke about this issue also 
varied in their opinions. One concurred with R4 and 
R19, commenting that it was not ‘ethical to approach 
people who are grieving in that way’ (P23). Another 
acknowledged the considerable difficulties involved but 
was doubtful whether these justified ‘withholding’ infor-
mation about a patient’s research participation from 
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er, wrong to not be able to give people that information. 
So, um, so I don’t know’. (P6)
DISCUSSION
Our findings add empirical evidence about some of the 
difficulties that underlie previously reported problems in 
recruiting to ICU studies. Others have commented that 
studies in critical and emergency settings rarely reported 
detailed reasons for recruitment problems7—our study 
provides an in- depth account of the reasons why these 
studies encounter recruitment difficulties and points to 
several ways to address these difficulties (see box 3).
Reflecting the regulations governing research, partic-
ipants regarded informed consent by the patient as the 
most acceptable form of consent but emphasised that it 
was impossible to seek such consent when patients lacked 
decisional capacity. As others have similarly found,26 27 
researchers reported variation in how RECs responded to 
their proposed consent processes, with a few reporting 
that some RECs were reluctant to approve consent 
processes that were commonly used in ICU studies. These 
findings point to the continued importance of ensuring 
RECs that review ICU studies having relevant expertise 
and understanding of recruitment and consent for ICU 
studies. For ICU studies with very narrow recruitment 
time windows, researchers spoke about the potential 
benefits of RWPC. A few had considered RWPC for their 
studies, but felt that RECs would not approve this process 
so they did not pursue it. Researchers wanted further 
guidance from RECs on the use of RWPC to ensure 
studies appropriately balanced both ethical and scientific 
considerations. Box 3 summarises these and other factors 
that could benefit recruitment to ICU studies.
The accounts of both researchers and PPI contribu-
tors indicated that PPI activity was largely limited to the 
development of study information materials for patients 
and families. Researchers who involved PPI contributors 
more broadly pointed to the value of their input, partic-
ularly in helping to resolve questions about consent 
processes, such as the use of professional consultees and 
the disclosure of study enrolment to bereaved families. 
This echoes findings from other research contexts where 
PPI was found to be helpful in addressing various chal-
lenges and ensuring research was acceptable and relevant 
to patients.27–29 Extending PPI beyond the development 
of study information materials to the design, planning 
and implementation of studies could benefit critical care 
research, although PPI contributors would need support 
and training to help them feel confident in commenting 
on ICU study consent processes. We have developed 
an accessible animation that could help as part of such 
training.30
In describing the implementation of recruitment and 
consent processes, researchers and PPI contributors 
were clear that recruiting patients would benefit from 
improved staffing and resourcing, as others have previ-
ously reported.14 Researchers were also concerned to 
avoid adding to the distress of families when recruiting to 
studies, but family members often had to be approached 
about research during or soon after a patient’s admission 
to ICU. Some researchers described deliberating over 
when to use personal or professional consultees in such 
situations; where studies involved interventions that were 
well understood or had particularly tight timescales, a 
few described using professional consultees rather than 
personal consultees to avoid distressing families. Others 
regarded the use of professional consultees as question-
able and avoided it altogether. Accounts also differed on 
the acceptability of approaching families by telephone 
to discuss research. Our findings resemble those from 
other contexts31–33 in pointing to the uncertainties and 
dilemmas that some researchers experience in recruiting 
to studies and to how researchers can gain confidence in 
recruiting and consenting to studies from knowing that 
the perspectives of patients and families have informed 
study protocols. There are also indications that the use of 
telephone consent in the UK has increased in response 
to the COVID-19 pandemic, given the restrictions in 
hospital visiting rules and risk of infection.34 Including 
specific advice in study protocols on issues such as the 
use professional consultees and approaching families by 
telephone to discuss research, informed by evidence on 
the perspectives of patients and other stakeholders and 
coproduced with PPI contributors, could help to address 
remaining uncertainty in these areas and potentially help 
to avoid non- recruitment of eligible patients.
Variations were also evident when participants spoke 
about situations where a patient had been recruited to 
a study under a professional consultee process and the 
patient later died before the family had been informed 
about the study. Researchers wanted further guidance on 
Box 3 Factors that could benefit recruitment and consent 
to intensive care unit (ICU) studies
 ► Ensuring that research ethics committees which review ICU stud-
ies have relevant expertise and understanding of recruitment and 
consent for studies involving incapacitated patients within narrow 
time windows.
 ► Widening the scope of patient–public involvement (PPI) in ICU stud-
ies and supporting PPI contributors to feel confident in contributing 
to the design of recruitment and consent processes.
 ► Better staffing for recruiting patients.
 ► Evidence on the perspectives of patients, relatives and staff regard-
ing recruitment and consent processes in adult critical care studies.
 ► Guidance on:
Requirements for ethical approval of research without prior consent.
Circumstances in which to use a professional consent/consultee 
process.
Use of telephone or videoconferencing to discuss research with 
relatives.
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whether to disclose to bereaved family members that their 
relative had been recruited to a study. Including specific 
advice on this in study protocols informed by evidence on 
families’ perspectives and codeveloped with PPI contrib-
utors could inform management of this sensitive issue. 
Such an approach has been useful in addressing method-
ological challenges in organ donation research,35 while 
research evidence on stakeholders’ perspectives has been 
pivotal in informing guidance on bereavement in the 
context of the critical care studies involving children.36–38 
Evidence on the perspectives of patients, relatives and 
staff regarding consent processes in adult critical care 
studies has been collected as part of the wider perspec-
tives study and could be similarly informative on this and 
other issues.
Our study has some limitations. First, despite trying 
different ways to access PPI contributors with experience 
of ICU studies, we interviewed fewer than anticipated, at 
least in part because researchers tended to rely on a small 
pool of PPI contributors for their studies. It is possible 
that the perspectives of the PPI contributors who we inter-
viewed do not reflect the breadth of PPI in ICU studies. 
Nevertheless, most researchers similarly described that 
the scope of PPI in ICU studies was limited. Second, inter-
views took place between late 2016 and mid 2017 and PPI 
input to ICU studies may have expanded since. Third, 
most of the studies discussed in the interviews were inter-
ventional and there may be distinct issues in recruiting 
and consenting to observational ICU studies that our 
findings do not cover. Finally, all participants were UK 
based. Cultural, legal and practice differences between 
counties means that caution is needed in transferring the 
findings to other countries.
In conclusion, this study offers insights on the prob-
lems that research teams encounter in recruiting and 
consenting to ICU studies and ways these could poten-
tially be overcome. Our findings indicate that the crit-
ical care research could benefit from further support 
and guidance in the areas summarised in box 3 above. 
Widening the scope of PPI in ICU studies and using 
evidence on the perspectives of patients and relatives to 
inform recruitment and consent to studies may be partic-
ularly important. Insights from these can help to ensure 
that protocols and guidance are patient centred, as well as 
help research teams to feel more confident in recruiting 
and consenting to studies.
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